In addition, the mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target in T2DM and NASH due to its activation of the AMPK/mTOR axis [135]. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatohepatitis.